Safety and Efficacy of Linagliptin in Type-2-diabetes Mellitus Patients With Moderate to Severe Renal Impairment
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT01087502 |
|
Recruitment Status :
Completed
First Posted : March 16, 2010
Results First Posted : October 17, 2013
Last Update Posted : June 27, 2014
|
Sponsor:
Boehringer Ingelheim
Collaborator:
Eli Lilly and Company
Information provided by (Responsible Party):
Boehringer Ingelheim
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Brief Summary:
The objective of the current study is to investigate the efficacy, safety and tolerability of linagliptin (5 mg / once daily) compared to placebo given over 12 weeks in drug naive or previously treated type 2 diabetic patients with moderate to severe renal impairment and insufficient glycaemic control. In addition safety in this patient population with longer term (40 week) treatment in comparison to sulfonylurea drug (glimepiride).
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Diabetes Mellitus, Type 2 | Drug: Glimepiride Drug: Placebo Drug: Linagliptin | Phase 3 |
| Study Type : | Interventional (Clinical Trial) |
| Actual Enrollment : | 241 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | Double |
| Primary Purpose: | Treatment |
| Official Title: | A Phase III, Randomised, Double-blind, Placebo-controlled Parallel Group Safety and Efficacy Study of Linagliptin (5 mg Administered Orally Once Daily) Over 12 Weeks Followed by a 40 Week Double-blind Extension Period (Placebo Patients Switched to Glimepiride) in Drug Naive or Previously Treated Type 2 Diabetic Patients With Moderate to Severe Renal Impairment and Insufficient Glycaemic Control |
| Study Start Date : | March 2010 |
| Actual Primary Completion Date : | May 2012 |
Resource links provided by the National Library of Medicine
MedlinePlus Genetics related topics:
Type 2 diabetes
| Arm | Intervention/treatment |
|---|---|
|
Experimental: Linagliptin
52 weeks treatment
|
Drug: Placebo
Placebo maching Glimepiride 1-4 mg after 12 weeks of treatment Drug: Linagliptin 5 mg once daily |
|
Placebo Comparator: Placebo
First 12 weeks of treatment
|
Drug: Placebo
Placebo mach to 5 mg linagliptin first 12 weeks of treatment once daily |
|
Active Comparator: Glimepiride
Placebo patients switch to glimepiride after 12 weeks (40 weeks treatment)
|
Drug: Glimepiride
1-4 mg daily after 12 weeks Drug: Placebo Placebo mach to 5 mg linagliptin once daily after 12 weeks |
Primary Outcome Measures :
- HbA1c Change From Baseline to Week 12 [ Time Frame: Baseline and week 12 ]HbA1c is measured as a percentage. Thus, this change from baseline reflects the Week 12 HbA1c percent minus the baseline HbA1c percent. Means are treatment adjusted for baseline HbA1c, renal function impairment and prior use of antidiabetic agents.
Secondary Outcome Measures :
- HbA1c Change From Baseline Over Time [ Time Frame: Baseline, week 4, week 8, week 12, week 16, week 20, week 24, week 28, week 34, week 40, week 46, week 52 ]HbA1c is measured as a percentage. Thus, this change from baseline reflects the HbA1c percent over time minus the baseline HbA1c percent. This outcome measure only provides descriptive statistics without any modelling.
- Fasting Plasma Glucose (FPG) Change From Baseline to Week 12 [ Time Frame: Baseline and week 12 ]This change from baseline reflects the Week 12 FPG minus the baseline FPG. Means are treatment-adjusted for baseline HbA1c, baseline FPG and prior use of insulin, week repeated within patient and week by treatment interaction.
- Fasting Plasma Glucose (FPG) Change From Baseline Over Time [ Time Frame: Baseline, week 4, week 8, week 12, week 20, week 24, week 28, week 34, week 40, week 46, week 52 ]This change from baseline reflects the FPG over time minus the baseline FPG. This outcome measure only provides descriptive statistics without any modelling.
- Percentage of Patients With HbA1c <7.0% [ Time Frame: Baseline, week 12 and week 52 ]The percentage of patients with an HbA1c value below 7% at week 12 and week 52 were calculated for each treatment arm. If a patient did not have an HbA1c value at week 12 or 52 respectively, they were considered a failure, so HbA1c above 7%.
- Percentage of Patients With HbA1c <6.5% [ Time Frame: Baseline, week 12 and week 52 ]The percentage of patients with an HbA1c value below 6.5% at week 12 and week 52 was calculated for each treatment arm. If a patient did not have an HbA1c value at week 12 or 52 respectively they were considered a failure, so HbA1c above 6.5%.
- Percentage of Patients Who Have a HbA1c Lowering by at Least 0.5% [ Time Frame: Baseline, week 12 and week 52 ]The percentage of patients with an HbA1c reduction of ≥0.5% at week 12 and week 52 from baseline was calculated for each treatment arm. If a patient did not have an HbA1c value at week 12 or 52 respectively they were considered a failure, so HbA1c reduction less than 0.5%.
- Plasma Concentration of Linagliptin at Trough [ Time Frame: Week 12, 24 and 52 ]Trough levels of concentration of Linagliptin in plasma.
Information from the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion criteria:
- Type 2 diabetes mellitus
- GFR<60 ml/min
- HbA1c >=7.0% to <= 10%
- Age >= 18 years
- BMI <=45 kg/m2
- Signed and dated written informed consent
Exclusion criteria:
- Myocardial infarction, stroke or TIA within 3 months prior to informed consent
- Renal impairment requiring dialysis
- Bariatric surgery
- Impaired hepatic function
- Treatment with glitazones, GLP-1 analogues, DPP-4 inhibitors
- Treatment with anti-obesity drugs
- Treatment with SU, glinides and metformin 8 weeks prior to informed consent
Information from the National Library of Medicine
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01087502
Locations
Show 52 study locations
Sponsors and Collaborators
Boehringer Ingelheim
Eli Lilly and Company
Investigators
| Study Chair: | Boehringer Ingelheim | Boehringer Ingelheim |
| Responsible Party: | Boehringer Ingelheim |
| ClinicalTrials.gov Identifier: | NCT01087502 |
| Other Study ID Numbers: |
1218.64 2009-016971-31 ( EudraCT Number: EudraCT ) |
| First Posted: | March 16, 2010 Key Record Dates |
| Results First Posted: | October 17, 2013 |
| Last Update Posted: | June 27, 2014 |
| Last Verified: | May 2014 |
Additional relevant MeSH terms:
|
Diabetes Mellitus Diabetes Mellitus, Type 2 Glucose Metabolism Disorders Metabolic Diseases Endocrine System Diseases Glimepiride Linagliptin Anti-Arrhythmia Agents Hypoglycemic Agents Physiological Effects of Drugs |
Immunosuppressive Agents Immunologic Factors Incretins Hormones Hormones, Hormone Substitutes, and Hormone Antagonists Dipeptidyl-Peptidase IV Inhibitors Protease Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action |